Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer

British Journal of Cancer

Volumn 99, Issue 11, 2008, Pages 1763-1768

  McCowan, C ^a   Shearer, J ^b   Donnan, P T ^a   Dewar, J A ^b   Crilly, M ^c   Thompson, A M ^b   Fahey, T P ^a,d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Adherence; Breast cancer; Community; Mortality; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 56749152357     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604758     Document Type: Article

References (30)

1. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. In Cancer 109: 832-839
2. Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis Part III: multivariate data analysis - choosing a model and assessing its adequacy and fit. Br J Cancer 89: 605-611
3. Burstein HJ, Winer EP (2000) Primary care for survivors of breast cancer. New Engl J Med 343: 1086-1094
4. Carstairs V, Morris R (1990) Deprivation and health in Scotland. Health Bull 48: 162-175
5. Chlebowski RT, Geller ML, Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71: 1-9
6. Clark TG, Bradburn MJ, Love SB, Altman DG (2003) Survival analysis part I: basic concepts and first analyses. Brit J Cancer 89: 232-238
7. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y, Early Breast Cancer Trialists' Collaborative G (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366: 2087-2106
8. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19: 322-328
9. Dewar JA, Stewart HJ, MacDonald TM (1996) Tamoxifen compliance in a clinical trial. Breast 5: 152-153
10. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45: 613-619
11. DiMatteo MR (2004) Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 42: 200-209
12. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
13. Early Breast Cancer Trialists' Collaborative Group (2004) Tamoxifen for early breast cancer. Cochrane Database of Systematic Reviews, Reviews 2008 Issue 4. John Wiley & Sons, Ltd.: Chichester, UK
14. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA, Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor - positive breast cancer. J Clin Oncol 22: 3309-3315
15. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527-537
16. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529-1542
17. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93: 684-690
18. Grunfeld EA, Hunter MS, Sikka P, Mittal S, Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59: 97-102
19. McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288: 2868-2879
20. Murthy V, Bharia G, Sarin R (2002) Tamoxifen non-compliance: does it matter? Lancet Oncol 3: 654
21. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. New Engl J Med 339: 1609-1618
22. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353: 487-497
23. Owusu C, Buist DSM, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Ulcickas Yood M, Wei F, Silliman RA (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor positive breast cancer. J Clin Oncol 26: 3125-3127
24. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21: 602-606
25. Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, Prescott RJ, George WD (1996) Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Brit J Cancer 74: 297-299
26. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA (2004) New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 57: 1288-1294
27. Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst 88: 1543-1549
28. Wang J, Donnan PT (2001) Propensity score methods in drug safety studies: practice, strengths and limitations. Pharmacoepidemiology & Drug Saftey 10: 341-344
29. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM (2002) Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart (British Cardiac Society) 88: 229-233
30. Yood MU, Owusu C, Buist DS, Geiger AM, Field TS, Thwin SS, Lash TL, Prout MN, Wei F, Quinn VP, Frost FJ, Silliman RA (2008) Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 206: 66-75